Overcoming the challenges in translational development of natural killer cell therapeutics: An opinion paper.

Qin, Hong; You, Changqiao; Yan, Feng; Tan, Kefang; Xu, Changgen; Zhao, Rui; Ekpo, Marlene Davis; Tan, Songwen

Qin, Hong; You, Changqiao; Yan, Feng; Tan, Kefang; Xu, Changgen; Zhao, Rui; Ekpo, Marlene Davis; Tan, Songwen.

Afiliação

Qin H; Research and Development Department, NanHua Bio-medicine CO., Ltd., Changsha, China.
You C; Research and Development Department, NanHua Bio-medicine CO., Ltd., Changsha, China.
Yan F; Research and Development Department, NanHua Bio-medicine CO., Ltd., Changsha, China.
Tan K; Research and Development Department, NanHua Bio-medicine CO., Ltd., Changsha, China.
Xu C; Research and Development Department, NanHua Bio-medicine CO., Ltd., Changsha, China.
Zhao R; Xiangya School of Pharmaceutical Sciences, Central South University, Changsha, China.
Ekpo MD; Xiangya School of Pharmaceutical Sciences, Central South University, Changsha, China.
Tan S; Xiangya School of Pharmaceutical Sciences, Central South University, Changsha, China.

Front Oncol ; 12: 1062765, 2022.

Article em En | MEDLINE | ID: mdl-36531041

Palavras-chave

biotherapeutics; cancer; chemotherapy; immunosenescence; immunotherapy; natural killer (NK) cells

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Front Oncol Ano de publicação: 2022 Tipo de documento: Article País de afiliação: China

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google